Research programme: complement factor D inhibitors - Achillion Pharmaceuticals

Drug Profile

Research programme: complement factor D inhibitors - Achillion Pharmaceuticals

Alternative Names: ACH CFDIS

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Achillion Pharmaceuticals
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Complement factor D inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Chronic obstructive pulmonary disease

Most Recent Events

  • 22 Feb 2018 Achillion Pharmaceuticals has patent protection for factor D inhibitors, with patents for subfamilies pending, in USA
  • 21 Mar 2017 Achillion Pharmaceuticals has issued and pending patents for complement factor-D inhibitors in USA
  • 21 Mar 2017 USPTO issues Notices of Allowance for four patent applications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top